The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.

Alector, US-based immuno-neurology therapy developer backed by corporates AbbVie, Eli Lilly, Alphabet, Amgen and Merck & Co, will raise $176m when it floats on the Nasdaq Global Select Market today. The company priced 9.25 million shares at $19.00 each, in the middle of the $18 to $20 range it set for the initial public offering,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.